PARP inhibitor improves progression-free survival in patients with advanced breast cancers and BRCA mutations
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
The results of the EMBRACA trial were presented today at the 2017 San Antonio Breast Cancer...
Ribociclib extends progression-free survival in pre-menopausal patients with metastatic hormone receptor-positive breast cancer
The addition of ribociclib, an inhibitor of the cell cycle, to standard hormone therapy significantly improved progression-free survival (...